OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
Luteolin inhibits Nrf2 leading to negative regulation of the Nrf2/ARE pathway and sensitization of human lung carcinoma A549 cells to therapeutic drugs
Xiuwen Tang, Hongyan Wang, Longfang Fan, et al.
Free Radical Biology and Medicine (2011) Vol. 50, Iss. 11, pp. 1599-1609
Closed Access | Times Cited: 302
Xiuwen Tang, Hongyan Wang, Longfang Fan, et al.
Free Radical Biology and Medicine (2011) Vol. 50, Iss. 11, pp. 1599-1609
Closed Access | Times Cited: 302
Showing 1-25 of 302 citing articles:
Therapeutic targeting of the NRF2 and KEAP1 partnership in chronic diseases
Antonio Cuadrado, Ana I. Rojo, Geoffrey Wells, et al.
Nature Reviews Drug Discovery (2019) Vol. 18, Iss. 4, pp. 295-317
Open Access | Times Cited: 1072
Antonio Cuadrado, Ana I. Rojo, Geoffrey Wells, et al.
Nature Reviews Drug Discovery (2019) Vol. 18, Iss. 4, pp. 295-317
Open Access | Times Cited: 1072
Small Molecule Modulators of K eap1‐N rf2‐ARE Pathway as Potential Preventive and Therapeutic Agents
Sadagopan Magesh, Yu Chen, Longqin Hu
Medicinal Research Reviews (2012) Vol. 32, Iss. 4, pp. 687-726
Open Access | Times Cited: 695
Sadagopan Magesh, Yu Chen, Longqin Hu
Medicinal Research Reviews (2012) Vol. 32, Iss. 4, pp. 687-726
Open Access | Times Cited: 695
The Keap1–Nrf2–ARE Pathway As a Potential Preventive and Therapeutic Target: An Update
Mengchen Lu, Jianai Ji, Zhengyu Jiang, et al.
Medicinal Research Reviews (2016) Vol. 36, Iss. 5, pp. 924-963
Closed Access | Times Cited: 678
Mengchen Lu, Jianai Ji, Zhengyu Jiang, et al.
Medicinal Research Reviews (2016) Vol. 36, Iss. 5, pp. 924-963
Closed Access | Times Cited: 678
Toward clinical application of the Keap1–Nrf2 pathway
Takafumi Suzuki, Hozumi Motohashi, Masayuki Yamamoto
Trends in Pharmacological Sciences (2013) Vol. 34, Iss. 6, pp. 340-346
Closed Access | Times Cited: 628
Takafumi Suzuki, Hozumi Motohashi, Masayuki Yamamoto
Trends in Pharmacological Sciences (2013) Vol. 34, Iss. 6, pp. 340-346
Closed Access | Times Cited: 628
The Dual Roles of NRF2 in Cancer
Silvia Menegon, Amedeo Columbano, Silvia Giordano
Trends in Molecular Medicine (2016) Vol. 22, Iss. 7, pp. 578-593
Open Access | Times Cited: 564
Silvia Menegon, Amedeo Columbano, Silvia Giordano
Trends in Molecular Medicine (2016) Vol. 22, Iss. 7, pp. 578-593
Open Access | Times Cited: 564
Modulating ROS to overcome multidrug resistance in cancer
Qingbin Cui, Jing‐Quan Wang, Yehuda G. Assaraf, et al.
Drug Resistance Updates (2018) Vol. 41, pp. 1-25
Closed Access | Times Cited: 557
Qingbin Cui, Jing‐Quan Wang, Yehuda G. Assaraf, et al.
Drug Resistance Updates (2018) Vol. 41, pp. 1-25
Closed Access | Times Cited: 557
Activators and Inhibitors of NRF2: A Review of Their Potential for Clinical Development
Natalia Robledinos-Antón, Raquel Fernández-Ginés, Gina Manda, et al.
Oxidative Medicine and Cellular Longevity (2019) Vol. 2019, pp. 1-20
Open Access | Times Cited: 525
Natalia Robledinos-Antón, Raquel Fernández-Ginés, Gina Manda, et al.
Oxidative Medicine and Cellular Longevity (2019) Vol. 2019, pp. 1-20
Open Access | Times Cited: 525
The KEAP1–NRF2 System in Cancer
Keiko Taguchi, Masayuki Yamamoto
Frontiers in Oncology (2017) Vol. 7
Open Access | Times Cited: 443
Keiko Taguchi, Masayuki Yamamoto
Frontiers in Oncology (2017) Vol. 7
Open Access | Times Cited: 443
RXRα Inhibits the NRF2-ARE Signaling Pathway through a Direct Interaction with the Neh7 Domain of NRF2
Hongyan Wang, Kaihua Liu, Miao Geng, et al.
Cancer Research (2013) Vol. 73, Iss. 10, pp. 3097-3108
Open Access | Times Cited: 326
Hongyan Wang, Kaihua Liu, Miao Geng, et al.
Cancer Research (2013) Vol. 73, Iss. 10, pp. 3097-3108
Open Access | Times Cited: 326
Natural product-derived pharmacological modulators of Nrf2/ARE pathway for chronic diseases
Hemant Kumar, In‐Su Kim, Sandeep Vasant More, et al.
Natural Product Reports (2013) Vol. 31, Iss. 1, pp. 109-139
Closed Access | Times Cited: 316
Hemant Kumar, In‐Su Kim, Sandeep Vasant More, et al.
Natural Product Reports (2013) Vol. 31, Iss. 1, pp. 109-139
Closed Access | Times Cited: 316
The Nrf2/HO‐1 Axis in Cancer Cell Growth and Chemoresistance
Anna Lisa Furfaro, N. Traverso, Cinzia Domenicotti, et al.
Oxidative Medicine and Cellular Longevity (2015) Vol. 2016, Iss. 1
Open Access | Times Cited: 267
Anna Lisa Furfaro, N. Traverso, Cinzia Domenicotti, et al.
Oxidative Medicine and Cellular Longevity (2015) Vol. 2016, Iss. 1
Open Access | Times Cited: 267
The Nrf2-ARE signaling pathway: An update on its regulation and possible role in cancer prevention and treatment
Violetta Krajka‐Kuźniak, Jarosław Paluszczak, Wanda Baer‐Dubowska
Pharmacological Reports (2016) Vol. 69, Iss. 3, pp. 393-402
Closed Access | Times Cited: 253
Violetta Krajka‐Kuźniak, Jarosław Paluszczak, Wanda Baer‐Dubowska
Pharmacological Reports (2016) Vol. 69, Iss. 3, pp. 393-402
Closed Access | Times Cited: 253
NRF2 as a regulator of cell metabolism and inflammation in cancer
Feng He, Laura Antonucci, Michael Karin
Carcinogenesis (2020) Vol. 41, Iss. 4, pp. 405-416
Open Access | Times Cited: 237
Feng He, Laura Antonucci, Michael Karin
Carcinogenesis (2020) Vol. 41, Iss. 4, pp. 405-416
Open Access | Times Cited: 237
Inhibition of cancer antioxidant defense by natural compounds
Alicja Sznarkowska, Anna Kostecka, Katarzyna Meller, et al.
Oncotarget (2016) Vol. 8, Iss. 9, pp. 15996-16016
Open Access | Times Cited: 202
Alicja Sznarkowska, Anna Kostecka, Katarzyna Meller, et al.
Oncotarget (2016) Vol. 8, Iss. 9, pp. 15996-16016
Open Access | Times Cited: 202
Molecular and Chemical Regulation of the Keap1-Nrf2 Signaling Pathway
Young‐Sam Keum, Bu Young Choi
Molecules (2014) Vol. 19, Iss. 7, pp. 10074-10089
Open Access | Times Cited: 195
Young‐Sam Keum, Bu Young Choi
Molecules (2014) Vol. 19, Iss. 7, pp. 10074-10089
Open Access | Times Cited: 195
Brusatol provokes a rapid and transient inhibition of Nrf2 signaling and sensitizes mammalian cells to chemical toxicity—implications for therapeutic targeting of Nrf2
T.M.A. Olayanju, Ian M. Copple, Holly K. Bryan, et al.
Free Radical Biology and Medicine (2014) Vol. 78, pp. 202-212
Open Access | Times Cited: 192
T.M.A. Olayanju, Ian M. Copple, Holly K. Bryan, et al.
Free Radical Biology and Medicine (2014) Vol. 78, pp. 202-212
Open Access | Times Cited: 192
Ferroptosis mediated DSS-induced ulcerative colitis associated with Nrf2/HO-1 signaling pathway
Yeru Chen, Piao Zhang, Wenru Chen, et al.
Immunology Letters (2020) Vol. 225, pp. 9-15
Open Access | Times Cited: 171
Yeru Chen, Piao Zhang, Wenru Chen, et al.
Immunology Letters (2020) Vol. 225, pp. 9-15
Open Access | Times Cited: 171
Potential Applications of NRF2 Inhibitors in Cancer Therapy
Emiliano Panieri, Luciano Saso
Oxidative Medicine and Cellular Longevity (2019) Vol. 2019, pp. 1-34
Open Access | Times Cited: 161
Emiliano Panieri, Luciano Saso
Oxidative Medicine and Cellular Longevity (2019) Vol. 2019, pp. 1-34
Open Access | Times Cited: 161
NRF2: KEAPing Tumors Protected
Ray Pillai, Makiko Hayashi, Anastasia‐Maria Zavitsanou, et al.
Cancer Discovery (2022) Vol. 12, Iss. 3, pp. 625-643
Open Access | Times Cited: 118
Ray Pillai, Makiko Hayashi, Anastasia‐Maria Zavitsanou, et al.
Cancer Discovery (2022) Vol. 12, Iss. 3, pp. 625-643
Open Access | Times Cited: 118
The Hallmarks of Flavonoids in Cancer
Luis Gustavo Saboia Ponte, Isadora Carolina Betim Pavan, Mariana Camargo Silva Mancini, et al.
Molecules (2021) Vol. 26, Iss. 7, pp. 2029-2029
Open Access | Times Cited: 115
Luis Gustavo Saboia Ponte, Isadora Carolina Betim Pavan, Mariana Camargo Silva Mancini, et al.
Molecules (2021) Vol. 26, Iss. 7, pp. 2029-2029
Open Access | Times Cited: 115
Therapeutic Targeting of the NRF2 Signaling Pathway in Cancer
Pelin Telkoparan‐Akillilar, Emiliano Panieri, Dilek Cevik, et al.
Molecules (2021) Vol. 26, Iss. 5, pp. 1417-1417
Open Access | Times Cited: 109
Pelin Telkoparan‐Akillilar, Emiliano Panieri, Dilek Cevik, et al.
Molecules (2021) Vol. 26, Iss. 5, pp. 1417-1417
Open Access | Times Cited: 109
Astrocyte-oligodendrocyte interaction regulates central nervous system regeneration
Irene Molina-González, R. Holloway, Zoeb Jiwaji, et al.
Nature Communications (2023) Vol. 14, Iss. 1
Open Access | Times Cited: 57
Irene Molina-González, R. Holloway, Zoeb Jiwaji, et al.
Nature Communications (2023) Vol. 14, Iss. 1
Open Access | Times Cited: 57
Phenolic compounds as Nrf2 inhibitors: potential applications in cancer therapy
Javad Sharifi‐Rad, Véronique Seidel, Michalak Izabela, et al.
Cell Communication and Signaling (2023) Vol. 21, Iss. 1
Open Access | Times Cited: 53
Javad Sharifi‐Rad, Véronique Seidel, Michalak Izabela, et al.
Cell Communication and Signaling (2023) Vol. 21, Iss. 1
Open Access | Times Cited: 53
Nrf2 Pathway and Oxidative Stress as a Common Target for Treatment of Diabetes and Its Comorbidities
Michelle Yi, L Cisneros, E.J. Cho, et al.
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 2, pp. 821-821
Open Access | Times Cited: 18
Michelle Yi, L Cisneros, E.J. Cho, et al.
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 2, pp. 821-821
Open Access | Times Cited: 18
A Comprehensive Review of Various Therapeutic Strategies for the Management of Skin Cancer
Sudharshan Reddy Dachani, Mohammed Kaleem, Md Ali Mujtaba, et al.
ACS Omega (2024) Vol. 9, Iss. 9, pp. 10030-10048
Open Access | Times Cited: 15
Sudharshan Reddy Dachani, Mohammed Kaleem, Md Ali Mujtaba, et al.
ACS Omega (2024) Vol. 9, Iss. 9, pp. 10030-10048
Open Access | Times Cited: 15
